bioethics: Case Discussion I

["Prof. Baboo" <ksbaboo@coppernet.zm>]

>Dear all I have no problem of any body coming and doing research in Zambia.
>but there are certain atticates and mannerizms which need to be
>fallowed.Take for example the fallowing.
>1. Funding. 70% of the funding goes for the maintinance of the foreign
>collaboraters.
>2. Authership. you land up being 6th or 7th auther.
>3. Concent.It  is not uniform. US or UK regulatios are not applicable to the
>developing countries.Concent forms are often very bulky and time
>consuming.Translation is another issue.
>4. Insentives given to paricipants ofen comprises the research.
>5. Big question is those who are conducting HIV related studies, how many of
>these investigaters have trainig in Human Participants Protection Progarm or
>have OHRP certification to do HIV studies.
>6.Any new drug to be used in any country should be approved by the Drug and
>Poisons commission and the Reserch and Ethics committee (IRB) of individual
>countries.
>7. How do you bring reserch to places where there is no infra structure.By
>giving few computers and furniture here and there is not infrastructure
>development.
>8.CIOME, Helsinki Declaration and WHO guide lines are not uniform.There are
>no universal guidelines which are suitable to all.There fore the need to
>fallow each case by its own merit.
>   Prof K S Baboo
>Former Cair of Ethics Committee(1993-2000).University of Zambia.
>
>
>-----Original Message-----
>From: owner-bioethics@hsphsun2.harvard.edu
>[mailto:owner-bioethics@hsphsun2.harvard.edu]On Behalf Of
>nipuna@stmail.lk
>Sent: Monday, November 17, 2003 12:00 AM
>To: bioethics@hsphsun2.harvard.edu
>Subject: bioethics: Case Discussion - Double Standard for an AIDS Drug
>
>
>
> > >dear all
> > >
> > >This case brings out important ethical issues of international
> > >collaborations.
> > >
> > >1. Why they choose south African country to do a "rough comparison of
> > >efficacy" and to take quick and dirty first look
> > >
> > >Will any of the euro-American countries refuse such a study to be
>conducted
> > >in their country
> > >why did not they do it in France
> > >AIDS is not a tropical illness only
> > >will these institutions would show the same enthusiasm for developing
>drugs
> > >for dengue and malaria
> > >
> > >Developed countries should not do any clinical trials in the developing
> > >world exclusively for diseases that are common to both worlds. It only
> > >appears just if they do it simultaneously in both worlds or replicate a
> > >trial done in developed world.
> > >
> > >The case and the questions seems eurocentric as the main epistemological
> > >foundations of the bioethics
> > >
> > >sisira
> > >Dr Sisira Siribaddana
> > >Endocrinologist
> > >Researcher
> > >Sri lankan Twin Registry
> > >Coordinator
> > >Bio-ethics Initiative
> > >Forum for Research & Development
> > >Dedicated to build research capacity in Sri Lanka
> > >www.forumforresearch.org
> > >
> > >
> > >
> > >-
>
>
>*****
>Susie Welty
>Program Manager
>Program on Ethical Issues in International Health Research
>Department of Population and International Health
>Building I -- Room 1104
>Harvard School of Public Health
>665 Huntington Avenue
>Boston, MA  02115
>
>Telephone:      617-432-3998
>Fax:            617-566-0365
>E-mail: swelty@hsph.harvard.edu
>Website:        http://www.hsph.harvard.edu/bioethics


*****
Susie Welty
Program Manager
Program on Ethical Issues in International Health Research
Department of Population and International Health
Building I -- Room 1104
Harvard School of Public Health
665 Huntington Avenue
Boston, MA  02115

Telephone:      617-432-3998
Fax:            617-566-0365
E-mail: swelty@hsph.harvard.edu
Website:        http://www.hsph.harvard.edu/bioethics